New! You can now keep track of new articles from Clinical Therapeutics on your personalized homepage!
Background: Olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension are topical antiallergic agents indicated for treatment of the signs and symptoms of allergic conjunctivitis and seasonal allergic conjunctivitis (SAC), respectively. Objective: The...
Background: Recognizing acute exacerbations of chronic bronchitis (AECB) and selecting appropriate antibiotic treatment for patients who would benefit most is a challenge for community-based physicians. Objective: The Tequin Clinical Experience Study, an open-label, noncomparative, post-marketing...
Background: The addition of a nonsteroidal anti-inflammatory drug to the regimen of a patient with treated hypertension can cause a destabilization of blood pressure. Objective: The aim of this study was to describe physician-reported management of clinically significant edema and/or destabilized...
Background: Various drugs have been approved for the treatment of Alzheimer's disease (AD) in the United States and Canada, including donepezil and rivastigmine, although questions remain as to their efficacy, effectiveness, and long-term benefits. Objective: The goal of this study was to conduct...